modelLevosimendan
Extends from Pharmacolibrary.Drugs.ATC.C.C01CX08.
Information
| name: | Levosimendan | |
| ATC code: | C01CX08 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 12 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 3.0 | mL/min/kg |
| other parameters in model implementation | ||
Levosimendan is a calcium sensitizer and potassium channel opener used for short-term treatment of acute decompensated severe chronic heart failure in adults. It enhances myocardial contractility without increasing myocardial oxygen demand. It is approved in various countries but not in the United States.
Pharmacokinetics
Population pharmacokinetics in adult patients with severe heart failure following intravenous administration.
References
Jonsson, EN, et al., & Karlsson, MO (2003). Population pharmacokinetics of levosimendan in patients with congestive heart failure. British journal of clinical pharmacology 55(6) 544–551. DOI:10.1046/j.1365-2125.2003.01778.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12814448
Antila, S, et al., & Lehtonen, LA (2007). Clinical pharmacology of levosimendan. Clinical pharmacokinetics 46(7) 535–552. DOI:10.2165/00003088-200746070-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17596101
McBride, BF, & White, CM (2003). Levosimendan: implications for clinicians. Journal of clinical pharmacology 43(10) 1071–1081. DOI:10.1177/0091270003257217 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14517189
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)